Effects of orelabrutinib, a BTK inhibitor, on antibody‐mediated platelet destruction in primary immune thrombocytopenia
British Journal of Haematology · 2025
DOI: 10.1111/bjh.20045 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, 2025. Verfasst von Tian-Shu Yu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan City, Shandong Province, China. Hauptthemen laut MEDLINE: Agammaglobulinaemia Tyrosine Kinase, Purpura, Thrombocytopenic, Idiopathic, Blood Platelets, Pyrazines. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 54 Literaturangaben. Gefördert von: Natural Science Foundation of Zhejiang Province, Natural Science Foundation of Shandong Province, National Natural Science Foundation of China.
Abstract (Originalsprache)
Primary immune thrombocytopenia (ITP) is a haemorrhagic disorder with a complex pathogenesis, wherein autoreactive B‐cell‐mediated platelet destruction plays a crucial role. Bruton's tyrosine kinase (BTK) is widely expressed and essential for immune cells. Several BTK inhibitors have been used clinically to treat haematological malignancies, while few studies are focusing on the regulatory role of BTK in ITP. This study aims to explore the feasibility and underlying mechanisms of a novel BTK inhibitor orelabrutinib in the treatment of ITP through in vitro and in vivo experiments. Orelabrutinib could inhibit B‐cell receptor‐mediated B‐cell activation, proliferation, differentiation and pro‐inflammatory cytokine secretion. Transcriptome sequencing revealed that B cells of ITP patients were more hyper‐responsive in inflammation and secretion activity compared to healthy controls, and orelabrutinib might alter B‐cell status through downregulating ribosome and mitochondrial metabolism. Fcγ receptor‐mediated platelet phagocytosis and pro‐inflammatory cytokine production by macrophages were also suppressed by orelabrutinib. Furthermore, orelabrutinib treatment considerably elevated the platelet count in active ITP murine models by inhibiting plasma cell differentiation, anti‐platelet antibody production, pro‐inflammatory factor secretion and platelet phagocytosis in the livers and spleens. Taken together, orelabrutinib could serve as a potential therapeutic agent for ITP by blocking antibody‐mediated platelet destruction.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan City, Shandong Province, China.
- Department of Hematology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China.
- Shandong Provincial Key Laboratory of Immunohematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan City, Shandong Province, China.
- North China University of Science and Technology Affiliated Hospital, Tangshan City, Hebei Province, China.
- Leading Research Group of Scientific Innovation, Department of Science and Technology of Shandong Province, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan City, Shandong Province, China.
ORCID-Profile: Shou-Qing Han, Ling-Jun Wang, Yu Hou, Ya-Jing Zhao, Xin-Guang Liu
Förderung
- Natural Science Foundation of Zhejiang Province
- Natural Science Foundation of Shandong Province
- National Natural Science Foundation of China
- Young Taishan Scholar Foundation of Shandong Province
Zitieren
APA
Yu, T. S., Han, S. Q., Wang, L. J., Wang, H. Y., Ni, X. F., Wang, R. T., Li, G. S., Hou, Y., Peng, J., Yan, Z. Y., Zhao, Y. J., Hou, M., & Liu, X. G. (2025). Effects of orelabrutinib, a BTK inhibitor, on antibody‐mediated platelet destruction in primary immune thrombocytopenia. British Journal of Haematology. https://doi.org/10.1111/bjh.20045
Vancouver
Yu TS, Han SQ, Wang LJ, Wang HY, Ni XF, Wang RT, et al. Effects of orelabrutinib, a BTK inhibitor, on antibody‐mediated platelet destruction in primary immune thrombocytopenia. British Journal of Haematology. 2025. doi:10.1111/bjh.20045
BibTeX
@article{Yu2025,
author = {Yu, Tian-Shu and Han, Shou-Qing and Wang, Ling-Jun and Wang, Hao-Yi and Ni, Xiao-Fei and Wang, Ru-Ting and Li, Guo-Sheng and Hou, Yu and Peng, Jun and Yan, Zhen-Yu and Zhao, Ya-Jing and Hou, Ming and Liu, Xin-Guang},
title = {Effects of orelabrutinib, a BTK inhibitor, on antibody‐mediated platelet destruction in primary immune thrombocytopenia},
journal = {British Journal of Haematology},
year = {2025},
doi = {10.1111/bjh.20045}
}
EUVIMED